Technical Analysis for ALNY - Alnylam Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
F 138.31 1.53% 2.08
ALNY closed up 1.53 percent on Wednesday, April 14, 2021, on approximately normal volume.
Earnings due: May 4
*** please verify all earnings dates ***

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down
Historical ALNY trend table...

Date Alert Name Type % Chg
20 DMA Resistance Bearish 0.00%
Pocket Pivot Bullish Swing Setup 0.00%
Bollinger Band Squeeze Range Contraction 0.00%
Multiple of Ten Bearish Other 0.00%
Bollinger Band Squeeze Range Contraction 1.53%
Doji - Bullish? Reversal 1.53%
Bollinger Band Squeeze Range Contraction 2.43%
Fell Below 200 DMA Bearish 0.06%
Fell Below 20 DMA Bearish 0.06%
Bollinger Band Squeeze Range Contraction 0.06%
Older End-of-Day Signals for ALNY ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Rose Above 10 DMA about 16 hours ago
Rose Above 20 DMA about 17 hours ago
10 DMA Resistance about 17 hours ago
Up 3% about 17 hours ago
Rose Above Previous Day's High about 18 hours ago
View Earlier Intraday Alerts

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Alnylam Pharmaceuticals, Inc. Description

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, engages in discovering, developing, and commercializing novel therapeutics based on RNA interference (RNAi). Its principal programs under clinical or pre-clinical development include ALN-TTR comprising ALN-TTR02 and ALN-TTRsc for the treatment of transthyretin-mediated amyloidosis; ALN-AT3 for the treatment of hemophilia and rare bleeding disorders; ALN-AS1 for the treatment of acute intermittent porphyria; ALN-PCS for the treatment of hypercholesterolemia; and ALN-TMP for the treatment of hemoglobinopathies, including beta-thalassemia. The company's early stage program comprise ALN-AAT, an RNAi therapeutic targeting the mutant Z-allele in alpha-1-antitrypsin deficiency (AAT deficiency) for the treatment of AAT deficiency-associated liver disease. It also has two partner-based programs in clinical development, including ALN-RSV01 for the treatment of respiratory syncytial virus infection; and ALN-VSP for the treatment of liver cancers, as well as one candidate in pre-clinical development comprising ALN-HTT for the treatment of Huntington's disease. The company has strategic alliances with F. Hoffmann-La Roche Ltd; Arrowhead Research Corporation; Takeda Pharmaceutical Company Limited; Monsanto Company; Isis Pharmaceuticals, Inc.; Novartis Pharma AG; Medtronic, Inc.; Kyowa Hakko Kirin Co., Ltd.; Genzyme Corporation; The Medicines Company; Cubist Pharmaceuticals, Inc; Biogen Idec Inc.; and Ascletis Pharmaceuticals (Hangzhou) Co., Ltd. Alnylam Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Cambridge, Massachusetts.


Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Life Sciences Clinical Development Cholesterol Hemoglobin Liver Disease Amyloid Hemophilia Takeda Pharmaceutical Company Huntington's Disease Amyloidosis Antitrypsin Deficiency Spinal Muscular Atrophy Hemophilia A Rna Interference Alnylam Pharmaceuticals Genzyme Hypercholesterolemia Liver Cancer Thalassemia Transthyretin Hemoglobinopathies Therapeutic Gene Modulation Treatment Of Hemophilia Deficiency Acute Intermittent Porphyria Beta Thalassemia Liver Cancers Medtronic Monsanto

Is ALNY a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 178.41
52 Week Low 119.29
Average Volume 522,908
200-Day Moving Average 141.87
50-Day Moving Average 146.20
20-Day Moving Average 139.29
10-Day Moving Average 139.86
Average True Range 5.12
ADX 22.69
+DI 17.99
-DI 26.04
Chandelier Exit (Long, 3 ATRs ) 133.18
Chandelier Exit (Short, 3 ATRs ) 145.64
Upper Bollinger Band 146.33
Lower Bollinger Band 132.25
Percent B (%b) 0.43
BandWidth 10.11
MACD Line -1.87
MACD Signal Line -2.08
MACD Histogram 0.201
Fundamentals Value
Market Cap 16.07 Billion
Num Shares 116 Million
EPS -8.25
Price-to-Earnings (P/E) Ratio -16.76
Price-to-Sales 37.25
Price-to-Book 12.54
PEG Ratio -0.49
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 143.99
Resistance 3 (R3) 144.04 142.20 143.04
Resistance 2 (R2) 142.20 140.76 142.18 142.73
Resistance 1 (R1) 140.26 139.86 141.23 140.20 142.41
Pivot Point 138.42 138.42 138.91 138.39 138.42
Support 1 (S1) 136.47 136.97 137.45 136.42 134.21
Support 2 (S2) 134.63 136.08 134.61 133.89
Support 3 (S3) 132.69 134.63 133.58
Support 4 (S4) 132.63